Y2C

IMMU Double Bottom

Long
NASDAQ:IMMU   None
0
News out: Patients see significant and durable tumor shrinkage after receiving treatments with sacituzumab govitecan
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.